Mereo BioPharma Group plc (MREO) is seen as a mispriced biotech opportunity with potential for high returns. The company's recent setbacks are seen as temporary, with upcoming catalysts expected to drive the stock price up.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing